Background-The balance between benefit (ischemia protection) and risk (bleeding) is a key consideration in choosing the intensity of antiplatelet therapy for patients with acute coronary syndromes. The goals of this analysis were to identify baseline characteristics that independently predict bleeding and to determine how bleeding events impact the subsequent mortality in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38).
D ual antiplatelet therapy with aspirin and an oral P2Y 12 receptor antagonist has become routine in patients with acute coronary syndromes (ACS), and has been clearly shown to be superior to aspirin monotherapy. 1 However, in large randomized trials, the reduction in ischemic events associated with P2Y 12 receptor antagonism plus aspirin has been accompanied by an increased risk of bleeding. 2, 3 The large interindividual variation in response to clopidogrel, 4,5 associated with a significant impact on clinical outcome, 6 has motivated the evaluation of more potent oral P2Y 12 receptor antagonists, such as prasugrel 7 and ticagrelor. 8 The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated the superiority of more robust platelet inhibition with prasugrel compared with standard-dose clopidogrel in the prevention of recurrence of major ischemic events, particularly myocardial infarction. 7 However, an excess of bleeding was observed in the prasugrel group. The US Food and Drug Administration 9 and the European Medicines Agency 10 approved prasugrel, but added warnings indicating that it can cause serious bleeding. 9
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The importance of the balance between benefit (reduction of ischemic events) and risk (excess bleeding) in antithrombotic treatment has been underscored by recent reports showing that patients with ACS who suffered bleeding had significantly higher 30-day mortality rates than patients without bleeding. 11, 12 A potential long-term impact of bleeding on mortality for up to 1 year was suggested by some studies. 13, 14 The goals of the present analyses were to (1) identify variables that independently predict bleeding in patients treated with prasugrel or clopidogrel added to aspirin and planned early percutaneous coronary intervention (PCI) for ACS enrolled in the TRITON-TIMI 38 trial 7 and (2) determine the impact of bleeding on mortality in these patients.
Methods

Study Patients
The TRITON-TIMI 38 study was a double-blind phase 3 trial that randomized 13 608 patients with ACS undergoing planned PCI to prasugrel (nϭ6813; 60 mg loading dose, 10 mg/d maintenance dose) or clopidogrel (nϭ6795; 300 mg loading dose, 75 mg/d maintenance dose). 7 The primary efficacy end point of the trial was the composite of cardiovascular death, nonfatal MI, or nonfatal stroke. Exclusions to participation included an increased risk of bleeding, a history of anemia, thrombocytopenia, known intracranial pathology, or the use of a P2Y 12 receptor antagonist within 5 days before randomization. 15 All primary efficacy and key safety end points were adjudicated by an independent clinical events committee whose members were unaware of the assigned treatment.
Bleeding was defined according to TIMI criteria. 15 Transfusion was defined as any transfusion of whole blood or packed red cells related to bleeding. TIMI major bleeding was defined as intracerebral hemorrhage or clinically overt bleeding (including imaging) associated with a drop in hemoglobin of Ն5 g/dL (corrected for transfusion). TIMI minor bleeding was defined as any clinically overt bleeding (including imaging) associated with a drop in hemoglobin of 3 to Ͻ5 g/dL (corrected for transfusion). In the present article, serious bleeding was defined as TIMI major or TIMI minor bleeding. TIMI minimal bleeding was defined as all other clinically overt signs of hemorrhage (including imaging) that were associated with a fall in hemoglobin of Ͻ3 g/dL.
Statistical Analysis
The safety population (nϭ13 457), made up of all randomized subjects who received at least 1 dose of the study drug from TRITON-TIMI 38, was used for this analysis. Patients who had only coronary artery bypass grafting (CABG)-related bleeding (nϭ37) were excluded from this analysis. Thus, 13 420 patients of the 13 608 patients enrolled in TRITON-TIMI 38 were included in the present analysis (online-only Data Supplement Table I ). All non-CABGrelated bleeding events occurring within 7 days of the patient having received the last dose of study drug were included. Bleeding was analyzed for both the hospital period and the follow-up period of the trial (6 to 15 months; median follow-upϭ14.5 months).
Baseline characteristics are presented as meanϮSD or median (interquartile range) for continuous variables and frequencies for categorical variables. Baseline comparisons were made with t tests or Wilcoxon rank sum tests for continuous variables and 2 or Fisher test for categorical variables. Univariable Cox proportional hazards models were used to compare the incidence of different types of bleeding between prasugrel and clopidogrel. If there was no bleeding event in 1 group, the Fisher test was used for comparison. Creatinine clearance was estimated with the use of the Cockcroft-Gault formula.
Multivariable Cox proportional hazards models were fit to evaluate the association between baseline characteristics and the risk of serious bleeding in the entire cohort and were also evaluated separately in patients treated with prasugrel or clopidogrel. The results of these models were described using the hazard ratio (HR) with the associated 95% confidence interval (CI). The first analysis of all serious bleeding events included all treatment variables, type of qualifying event, baseline and procedural variables, and most of previously reported predictors of bleeding, such as the aspirin dose ( Table 1 and online-only Data Supplement Table II ). The second analysis of spontaneous bleeding events occurring after the qualify- ing events (Ͼ3 days after randomization) used the same covariables, but omitted those variables associated with instrumentation, such as the duration of intervention (online-only Data Supplement Table III) . Independent predictors for serious bleeding were ranked by the strength of association as assessed by Wald 2 values from the Cox model.
A novel biostatistical approach was used to analyze the dynamic nature of the impact and time dependency of bleeding on mortality. A multivariable Cox model for mortality, including all baseline variables independently predictive for mortality (PϽ0.05), treatment with prasugrel, and a propensity score for bleeding in all patients treated with either clopidogrel or prasugrel, was used (online-only Data Supplement Table IV ). The propensity score was based on a Cox model for time to bleeding, with the score (probability of bleeding) being estimated at the time of censoring or bleeding for each individual. We used a propensity score to adjust for the differences in those who bled and did not bleed, because bleeding was a postrandomization event that defined the comparisons we have made here. The effect of time since the bleeding event on mortality was assessed using multiple iterative landmark analyses. The landmark data set for a particular day (after bleeding) consisted of those subjects who were still alive on that day after their bleeding event and who were still alive on the same number of days after randomization in those who did not have a bleeding event. To control for the impact of the qualifying ACS on mortality, the comparator group of patients without a bleeding event was selected to have the same number of days since randomization as the number of the landmark day. For example, the patients in the landmark analysis at 40 days after bleeding consisted of subjects who were at least 40 days from their bleeding event and subjects who were at least 40 days from randomization (nonbleeding subjects). The time to event used in the analysis was measured from 40 days. A Cox model was fit with a binary variable for bleeding, which resulted in a HR for that landmark day. This process was repeated for every landmark day to 180 days. The HR and point-wise 95% CI for bleeding were then plotted against the landmark day. All analyses were performed using SAS (version 9.1, Cary, NC) and the R statistical program (R Foundation for Statistical Computing, Vienna, Austria). Further details on these analyses are described in the Statistical Appendix in the online-only Data Supplement.
Role of the Funding Source
TRITON-TIMI 38 was funded by Eli Lilly and Company and Daiichi Sankyo Company Ltd. No additional funding for this analysis was provided. For this analysis, an independent copy of the complete trial database provided to the TIMI Group was used. The academic authors prepared the manuscript and take full responsibility for its content. The sponsors had no editorial authority but had the opportunity to comment on the manuscript.
Results
Study Population and Predictors of Bleeding Events
The baseline characteristics of all 13 420 patients on whom this analysis is based are shown in the online-only Data Supplement Table I . Five hundred thirty-four patients (4.0%) experienced a serious bleeding event, which was instrumented in 238 patients, traumatic in 30 patients, and spontaneous in 266 patients. A large majority (73%) of the 268 serious bleeding events related to instrumentation or trauma occurred within the first 3 days after randomization. The median time to the 266 spontaneous serious bleeding events was 74 (interquartile range: 7, 190) days. Table 1 compares the baseline characteristics of the 534 patients who experienced a serious bleeding event and the 12 886 patients who did not. The former were significantly older, had a lower median body weight, were more frequently women, more often presented with a ST-segment elevation myocardial infarction as the qualifying event, and were more likely to have a history of hypertension. These patients also had a lower incidence of tobacco use and lower median hematocrit and creatinine clearance. Patients with serious bleeding were more frequently assigned to prasugrel, more often received femoral arterial access and a glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitor for intervention, and had a longer duration of the PCI procedure. Table 2 shows the incidence of serious bleeding events according to study treatment stratified into instrumented/ traumatic and spontaneous events. Fatal serious bleeding occurred in 21 patients (0.3%) treated with prasugrel and in 6 patients (0.1%) on clopidogrel (HR 3.50; 95% CI 1.41 to 8.68; Pϭ0.01). This excess of serious bleeding on prasugrel occurred in both instrumented/traumatic and spontaneous bleeding and was driven mainly by a higher incidence of bleeding from surgical sites (other than CABG) and gastrointestinal bleeding. Transfusions related to bleeding were more frequent in patients assigned to prasugrel (HR 1.33; 95% CI 1.07 to 1.67; Pϭ0.01). Minimal bleeding was also more frequent in patients assigned to prasugrel (HR 1.48; 95% CI 1.29 to 1.71; PϽ0.001), largely related to puncture site bleeding and epistaxis.
Using the multivariable Cox model ( Table 3 , full model: online-only Data Supplement Table II) , the following variables were identified as independently associated with serious bleeding of any cause (ordered by strength of association with bleeding): female sex, use of a GPIIb/IIIa inhibitor, duration of intervention, age, assignment to prasugrel, regional characteristics (enrollment in North America versus Eastern Europe and Middle East, Africa, or Asia-Pacific), admission diagnosis of ST-segment elevation myocardial infarction, femoral access for angiography, creatinine clearance, hypercholesterolemia, and arterial hypertension. The second multivariable Cox model (online-only Data Supplement Table  III ) identified the following variables as independently associated with spontaneous serious bleeding occurring after the index hospitalization (ordered by strength of association with bleeding): assignment to prasugrel, age, peripheral arterial disease, and hematocrit. In both models, prasugrel was an independent predictor for serious bleeding.
Of the entire cohort, history of stroke or transient ischemic attack (TIA) (HR 1.58; 95% CI 1.10 to 2.29; Pϭ0.01), age Ն75 years (HR 2.58; 95% CI 2.13 to 3.13; PϽ0.001), and body weight Ͻ60 kg (HR 2.30; 95% CI 1.74 to 3.05; PϽ0.001) each were associated with higher risks of serious bleeding overall. Patients in these groups had a higher absolute risk difference in serious bleeding between prasugrel and clopidogrel compared with patients not meeting these criteria (Table 4 ). In elderly patients and in patients with low body weight, the incidence of serious bleeding was higher in both treatment groups compared with the remaining cohort. In these 2 subgroups, treatment with prasugrel compared with clopidogrel was also associated with a higher rate of bleeding. However, the relative risk of prasugrel for serious bleeding was similar to that in the remaining cohort in both subgroups. Hazard ratio with 95% CI derived from Cox regression analysis. HR indicates hazard ratio; CI, confidence interval; TIMI, Thrombolysis In Myocardial Infarction; and CABG, coronary artery bypass grafting.
*Includes 1 patient with a fatal gastrointestinal hemorrhage while receiving the study medication but missing hemoglobin testing that, therefore, did not formally fulfill the criteria for TIMI major bleeding.
Impact of Serious Bleeding on Mortality
After adjustment for all significant baseline characteristics, serious bleeding was associated with an overall HR for mortality of 5.84 (95% CI 4.11 to 8.29; online-only Data Supplement Table IV ). Blood transfusion for bleeding was not included in the final model because it was not predictive for mortality after adjustment for baseline variables and bleeding. The curve of the iterative landmark analysis for mortality showed a steep decline of the HR for serious bleeding within the first week after the bleeding event (Figure) . Forty days after a serious bleeding event, the HR for mortality was 1.38 (95% CI 0.72 to 2.66; Pϭ0.33). Spontaneous bleeding events were associated with a higher hazard for death compared with instrumented/traumatic bleeding events. The HR declined steeply in the first few days after both spontaneous and instrumented/traumatic bleeding events and leveled out thereafter. Hazard ratios for instrumented/ traumatic and spontaneous bleeding did not differ statistically from 1.0 after Ϸ5 and Ϸ32 days, respectively, although a trend to excess mortality persisted in the spontaneous bleeding group.
The HRs for mortality after a serious bleeding event were 7.40 (95% CI 4.59 to 11.93) for prasugrel and 4.21 (95% CI 2.46 to 7.23) for clopidogrel (P for interaction between treatment group and bleeding for mortalityϭ0.24). Several sensitivity analyses excluding intracerebral hemorrhage, analyzing only instrumented bleeding, or excluding TIMI minor bleeding events showed that the findings were consistent with the findings shown in the Figure ( 
Discussion
Antiplatelet treatment intensified by adding clopidogrel to aspirin has been shown to reduce fatal and nonfatal ischemic events in patients with ACS. 2, 16 However, this approach is also associated with a higher incidence of bleeding. [17] [18] [19] Therefore, it is not surprising that treatment with prasugrel and other novel and potent P2Y 12 antagonists was associated with a higher incidence of several types of bleeding events. 20 The large sample size, long-term follow-up, well characterized population, adjudication of bleeding events, and opportunity to study patients with 2 drugs of differing potency are strengths of the analyzed cohort. This analysis provides 5 major findings: (1) Only a limited number of variables were found to be independently associated with serious bleeding in the entire cohort. Those most strongly associated with the risk of bleeding were female sex and advanced age, together with procedural characteristics; (2) Although prasugrel was independently associated with a higher risk of serious bleeding than clopidogrel, the strength of this association was less than the above-named clinical factors; (3) Assignment to prasugrel was principally associated with a higher frequency of serious gastrointestinal bleeding, bleeding at surgical sites, and more frequent nonserious nasal and vascular access site bleeding; (4) Blood transfusion for bleeding was not an independent predictor for mortality after full adjustment for all available variables and bleeding; and (5) the impact of bleeding events on mortality was great within the first few days. However, its impact on mortality waned rapidly and the HR was not significantly different from 1.0 after 40 days.
Understanding the differences in frequency and location of bleeding events between prasugrel and clopidogrel and knowing the strongest predictors of bleeding in patients on dual antiplatelet therapy can guide clinicians in choosing the optimal antiplatelet strategy for the individual patient and selecting strategies to avoid the most frequent types of bleeding events. Just as in other analyses investigating predictors of bleeding in patients receiving anticoagulant or fibrinolytic therapies, the main independent predictors of bleeding in the entire cohort were patient characteristics (eg, age, sex, and body weight), procedural characteristics, and use of a GPIIb/IIIa inhibitor. 21, 22 The latter, even when only applied for a short period of time, showed a stronger association with serious bleeding than assignment to prasug- rel. The differences between the independent predictors were less profound in the analysis of predictors of spontaneous bleeding. Prasugrel was the strongest predictor for spontaneous serious bleeding in this analysis.
The analyses of the 3 subgroups of patients highlighted in the warning section of the US Food and Drug Administration label for prasugrel 9 showed that history of stroke or TIA, age Ն75 years, and body weight Ͻ60 kg were also associated with a higher risk of serious bleeding in the entire cohort. In the elderly patients and in patients with low body weight, the relative risk for serious bleeding associated with the assignment to prasugrel compared with clopidogrel was similar, as in the main cohort, whereas the absolute risk of bleeding was elevated in both treatment arms compared with the main cohort. Therefore, clinicians should be aware of the higher risk of bleeding in patients with advanced age and with low body weight with either thienopyridine. However, in patients with a history of stroke or TIA, prasugrel, when compared with clopidogrel, was associated with higher relative and absolute risks for serious bleeding, driven mainly by a higher rate and proportion of intracranial bleeding events (6 out of 20 serious bleeding events with prasugrel).
The potential impact of serious bleeding on short-and long-term mortality is of clinical interest. [11] [12] [13] [14] 23 In the present analysis, we also found that serious bleeding with either thienopyridine is associated with a higher risk for death. In contrast to some of the previous investigations, 13, 14 we found, using a novel biostatistical approach described herein, that the impact of instrumented or traumatic serious bleeding on mortality was of short duration (ie, less than a week, as shown in the Figure) . However, serious spontaneous bleeding tended to have a longer impact on mortality, with a significantly elevated HR for approximately 1 month and a nonsignificant trend beyond that time. The more prolonged impact of spontaneous serious bleeding may be explained in part by the underlying conditions contributing to the bleeding event that were not fully represented by the available patient characteristics (eg, bleeding associated with colon cancer, which was the cause of death). However, such an analysis cannot distinguish causality from markers of residual risk not fully accounted for in this analysis.
Limitations
Several limitations warrant consideration. The eligibility criteria for TRITON-TIMI 38 excluded subjects with some features indicating increased risk of bleeding, such as low (2), other (1); clopidogrel: intracranial (3), gastrointestinal (1) .
Includes 1 patient with a fatal gastrointestinal hemorrhage while receiving the study medication but missing hemoglobin testing that, therefore, did not formally fulfill the criteria for TIMI major bleeding.
Figure.
Hazard ratios (red) and 95% confidence intervals (blue) for death according to time after different types of bleeding. Each red dot represents the hazard ratio for death at the corresponding day after bleeding event compared with patients at same time in the trial without bleeding event. The continuous blue lines show the 95% confidence intervals. platelet count, known bleeding diathesis, or known intracranial aneurysms. 15 Therefore, the absolute and relative risks of bleeding with either thienopyridine might be greater in a routine practice environment. The use of certain medications that can influence the risk of bleeding (eg, proton pump inhibitors, nonsteroidal antiinflammatory drugs, and selective serotonin reuptake inhibitors) was not completely characterized over time, and the use of these drugs was not random. Therefore, we cannot asses how the use of these drugs influenced the risk of bleeding. Even after adjustment, the possibility of residual confounding remains for the relationship between bleeding and mortality. Although invasive procedures or other treatments associated with an enhanced risk for bleeding were not randomized, patients were only enrolled if PCI was intended, and virtually all patients underwent PCI. For the outcome analysis, models were adjusted for baseline variables but not for subsequent treatments or events (eg, recurrent myocardial infarction) during follow-up. Although misclassification of bleeding events could have altered the results, if that occurred it would have biased the results toward the null. However, in this trial all end points were strictly defined and adjudicated by a blinded clinical events committee. A potential limitation of our approach was the possibility that the propensity score for bleeding would vary over time. However, we examined the effect of a time-dependent propensity score on the hazard ratio at multiple time points and found that it did not meaningfully impact the analysis.
Conclusions
The major predictors of serious bleeding in ACS patients treated with the thienopyridines prasugrel and clopidogrel were patient characteristics and procedural characteristics. Although treatment with prasugrel was an independent predictor of serious bleeding, other characteristics of the patient and of the procedure were also at least as important. When compared with clopidogrel, prasugrel was associated primarily with a higher incidence of bleeding at interventional sites as well as with gastrointestinal bleeding. Although serious bleeding was associated with a significant risk of excess mortality, that excess risk was time-limited after an intervention or trauma and limited to approximately 1 month after a spontaneous bleeding event. 
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